title: Psoriasis and metabolic syndrome in children: current data.
abstract: BACKGROUND
  The prevalence of cardiovascular and metabolic disorders in paediatric patients with psoriasis is not well established.
  
  
  OBJECTIVE
  To conduct a meta-analysis of previously published studies dealing with the occurrence of metabolic disorders in children with psoriasis.
  
  
  METHODS
  Data from 7 studies with a total of 965 children with psoriasis were analysed using a random effects model.
  
  
  RESULTS
  Prevalence of metabolic syndrome (MetS) was significantly higher in patients with psoriasis than in healthy controls (HCs). In most studies, significantly decreased levels of high-density lipoprotein (HDL) cholesterol were found in children with psoriasis. Mean level of HDL cholesterol in patients with psoriasis was 2.05 mg/dL lower than in HCs. Patients with psoriasis and HCs did not differ significantly in their mean triglyceride levels, although the difference was at a threshold of statistical significance. Mean level of fasting glucose in children with psoriasis was 5.75 mg/dL higher than in HCs (P < 0.01). The two groups did not differ significantly in mean waist circumference or in systolic and diastolic arterial pressures.
  
  
  CONCLUSIONS
  Decreased levels of HDL cholesterol and increased concentrations of fasting glucose may represent very early stages of MetS in children with psoriasis. However, a large population-based study is needed to establish the relationship between psoriasis and MetS in children, including the environmental, genetic and immunological factors leading to their co-occurrence.
authors.affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Pietrzak
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.|St. John's Cancer Center, Lublin, Poland.
authors.forename: E
authors.initials: E
authors.lastname: Grywalska
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Walankiewicz
authors.affiliation: Department of Dermatology, University of Rome G. Marconi, Rome, Italy.
authors.forename: T
authors.initials: T
authors.lastname: Lotti
authors.affiliation: Department of Clinical Immunology and Immunotherapy, Medical University of Lublin, Lublin, Poland.|St. John's Cancer Center, Lublin, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Roliński
authors.affiliation: Department of Internal Diseases, Medical University of Lublin, Lublin, Poland.
authors.forename: W
authors.initials: W
authors.lastname: Myśliński
authors.affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
authors.forename: P
authors.initials: P
authors.lastname: Chabros
authors.affiliation: Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland.
authors.forename: D
authors.initials: D
authors.lastname: Piekarska-Myślińska
authors.affiliation: Dermatologikum Hamburg and SCIderm Research Institute, Hamburg, Germany.
authors.forename: K
authors.initials: K
authors.lastname: Reich
mesh_terms: D001786:Blood Glucose; D002648:Child; D008076:Cholesterol, HDL / Q000032:analysis / Q000097:blood*; D006801:Humans; D024821:Metabolic Syndrome / Q000150:complications* / Q000453:epidemiology; D015995:Prevalence; D011565:Psoriasis / Q000097:blood / Q000150:complications*; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D014280:Triglycerides